Logo Image
News
OncClubAll Oncology NewsClinical Trials in Focus
Watch
Expert ConversationsShows & PodcastsNews & Analysis
Conferences
Conference CoverageConference Listing
Events
Giants of Cancer CareCME/CELive EventsScientific InterchangesState of the Science SummitNational Fellows ForumWebinars
More
Partners
Publications
All PublicationsSupplements
Resources
Consensus ViewpointsOncLive AppInteractive ToolsSponsored
Biomarker Consortium

Subscribe

  • News
  • Watch
  • Conferences
  • Events
  • Partners
  • Publications
  • Resources
  • Biomarker Consortium
  • Subscribe
  • AI for Oncology
  • Biosimilars
  • Brain Cancer
  • Breast Cancer
    • HER2+ Breast Cancer
  • CAR T-Cell Therapy
  • Disparities in Cancer Care
  • Gastrointestinal Cancer
    • Pancreatic Cancer
    • Hepatocellular Carcinoma
    • Gastric Cancer
    • Colorectal Cancer
  • Genitourinary Cancers
    • Urothelial Cancer
    • Prostate Cancer
  • Global Oncology
  • Graft-vs-Host Disease
  • Gynecologic Oncology
    • Ovarian Cancer
  • Head & Neck Cancers
  • Hematologic Oncology
    • Chronic Lymphocytic Leukemia
    • Non-Hodgkin Lymphoma
    • Mantle Cell Lymphoma
    • Multiple Myeloma
    • Myeloproliferative Neoplasms
  • Immuno-Oncology
  • Lung Cancer
  • Melanoma & Skin Cancer
  • Oncology Business Management
  • Pediatric Oncology
  • Precision Medicine in Oncology®
  • Sarcomas
  • Supportive Care
Spotlight -
The OncLive Insider app is live!|
CME Opportunities
Advertisement

Barbara Marino, PhD

Advertisement

Articles by Barbara Marino, PhD

Patient-Contributed Tumor Genetics Data: A Pathway to Better Drug Development?

ByBy Yair Benita, PhD,Barbara Marino, PhD,Aman Bhandari, PhD,Roni Zeiger, MD,Sachin H. Jain, MD, MBA
December 3rd 2014

Developing companion diagnostics has several associated challenges related to cost, access to samples, and clinical trial recruitment.

Advertisement

Latest Updated Articles

  • Patient-Contributed Tumor Genetics Data:  A Pathway to Better Drug Development?
    Patient-Contributed Tumor Genetics Data: A Pathway to Better Drug Development?

    December 3rd 2014



Advertisement
Advertisement

Trending on OncLive

1

Durvalumab Plus Enfortumab Vedotin Improves Survival in Cisplatin-Ineligible MIBC

2

Pembrolizumab Plus Radiation Fails to Improve Recurrence-Free Survival in Early-Stage High-Intermediate–Risk dMMR Endometrial Cancer

3

Tovecimig Plus Paclitaxel Improves ORR vs Paclitaxel Alone in Biliary Tract Cancer

4

LK101 Plus Tislelizumab Elicits Responses in Advanced NSCLC

5

DeLLphi-305 Data Support Frontline Maintenance Tarlatamab Plus Durvalumab as a New SOC in ES-SCLC

  • Advertise
  • About OncLive
  • Editorial Board
  • MJH Life Sciences brands
  • Contact Us
  • Privacy
  • Terms & Conditions
  • Do Not Sell My Information
Contact Info

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

Brand Logo
Download on Apple
Download on Google Play

© 2026 MJH Life Sciences®

All rights reserved.

Home
About Us
News
Contact Us